Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy ADT in High Risk Prostate Cancer with Initial Phase I NADIR Randomized Phase II Trial of Niraparib with Standard Combination Androgen Deprivation Therapy ADT and Radiotherapy in High Risk Prostate Cancer with Initial Phase I
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy INNOVATE INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Measuring Surgical Recovery After Radical Cystectomy
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy with Enzalutamide in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
A Phase III, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator?s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor ARPI, in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC - rechARge
Study Type: Treatment
Phase: III
NCTID: NCT06764485
Principal Investigator:
Haoran Li
A Phase II Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb20717 Alone or in Combination with Chemotherapy or Targeted Therapies in Selected Subjects with Metastatic Castration-Resistant Prostate Cancer
Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Darolutamide Plus Androgen Deprivation Therapy ADT Compared To Placebo Plus ADT In Patients With High-Risk Biochemical Recurrence BCR Of Prostate Cancer
NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation PREDICT-RT
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician?s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01
Study Type: Treatment
Phase: III
NCTID: NCT06120491
Principal Investigator:
Elizabeth Wulff-Burchfield